

## UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, DC 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR		ATTORNEY DOCKET NO.
09/423,093	11/01/99	REEVES	P	23541-01

HM32/0921

WILLIAM H DIPPERT COWAN LIEBOWITZ & LATMAN 1133 AVENUE OF THE AMERICAS NEW YORK NY 10036-6799

EXAMINER	
SISSON, B	

ART UNIT PAPER NUMBER

DATE MAILED:

09/21/00

Please find below and/or attached an Office communication concerning this application or proceeding.

**Commissioner of Patents and Trademarks** 

	Application No.	Applicant(s)
	09/423,093	REEVES ET AL.
Interview Summary	Examiner	Art Unit
	Bradley L. Sisson	1655
All participants (applicant, applicant's representative,	PTO personnel):	
(1) Bradley L. Sisson.	(3)	
(2) William H. Dippert, Reg. No. 26,723.	(4)	
Date of Interview: 20 September 2000.		
Type: a)⊠ Telephonic b)□ Video Conferenc c)□ Personal [copy given to: 1)□ applica	e ant 2)⊡ applicant's represe	entative]
Exhibit shown or demonstration conducted: d) Y If Yes, brief description:	es e)⊠ No.	
Claim(s) discussed: <u>1-42</u> .		
Identification of prior art discussed:		
Agreement with respect to the claims f)⊠ was read	ched. g)∏ was not reached	d. h)□ N/A.
Substance of Interview including description of the greached, or any other comments: <u>See Continuation</u>	eneral nature of what was agr <u>Sheet</u> .	reed to if an agreement was
(A fuller description, if necessary, and a copy of the allowable, if available, must be attached. Also, when allowable is available, a summary thereof must be a	e no copy of the amendments	iner agreed would render the claims s that would render the claims
i)⊠ It is not necessary for applicant to provie checked).	de a separate record of the su	ubstance of the interview(if box is
Unless the paragraph above has been checked, TH MUST INCLUDE THE SUBSTANCE OF THE INTERACTION has already been filed, APPLICANT IS GIVEN STATEMENT OF THE SUBSTANCE OF THE INTEREVERSE side or on attached sheet.	N ONE MONTH FROM THIS	INTERVIEW DATE TO FILE A
		·
		•
Evaminer Note: You must sign this form unless it is an	5 J	Lisson

Examiner Note: You must sign this form unless it is an

Attachment to a signed Office action.

Examiner's signature, if required



Manual of Patent Examining Procedure (MPEP), Section 713.04, Substance of Interview Must be Made of Record

A complete written statement as to the substance of any face-to-face, video conference, or telephone interview with regard to an application must be made of record in the application whether or not an agreement with the examiner was reached at the interview.

## Title 37 Code of Federal Regulations (CFR) § 1.133 Interviews

Paragraph (b)

In every instance where reconsideration is requested in view of an interview with an examiner, a complete written statement of the reasons presented at the interview as warranting favorable action must be filed by the applicant. An interview does not remove the necessity for reply to Office action as specified in §§ 1.111, 1.135. (35 U.S.C. 132)

37 CFR §1.2 Business to be transacted in writing.

All business with the Patent or Trademark Office should be transacted in writing. The personal attendance of applicants or their attorneys or agents at the Patent and Trademark Office is unnecessary. The action of the Patent and Trademark Office will be based exclusively on the written record in the Office. No attention will be paid to any alleged oral promise, stipulation, or understanding in relation to which there is disagreement or doubt.

The action of the Patent and Trademark Office cannot be based exclusively on the written record in the Office if that record is itself incomplete through the failure to record the substance of interviews.

It is the responsibility of the applicant or the attorney or agent to make the substance of an interview of record in the application file, unless the examiner indicates he or she will do so. It is the examiner's responsibility to see that such a record is made and to correct material inaccuracies which bear directly on the question of patentability.

Examiners must complete an interview Summary Form for each interview held where a matter of substance has been discussed during the interview by checking the appropriate boxes and filling in the blanks. Discussions regarding only procedural matters, directed solely to restriction requirements for which interview recordation is otherwise provided for in Section 812.01 of the Manual of Patent Examining Procedure, or pointing out typographical errors or unreadable script in Office actions or the like, are excluded from the interview recordation procedures below. Where the substance of an interview is completely recorded in an Examiners Amendment, no separate Interview Summary Record is required.

The Interview Summary Form shall be given an appropriate Paper No., placed in the right hand portion of the file, and listed on the "Contents" section of the file wrapper. In a personal interview, a duplicate of the Form is given to the applicant (or attorney or agent) at the conclusion of the interview. In the case of a telephone or video-conference interview, the copy is mailed to the applicant's correspondence address either with or prior to the next official communication. If additional correspondence from the examiner is not likely before an allowance or if other circumstances dictate, the Form should be mailed promptly after the interview rather than with the next official communication.

The Form provides for recordation of the following information:

- Application Number (Series Code and Serial Number)
- Name of applicant
- Name of examiner
- Date of interview
- Type of interview (telephonic, video-conference, or personal)
- Name of participant(s) (applicant, attorney or agent, examiner, other PTO personnel, etc.)
- An indication whether or not an exhibit was shown or a demonstration conducted
- An identification of the specific prior art discussed
- An indication whether an agreement was reached and if so, a description of the general nature of the agreement (may be by attachment of a copy of amendments or claims agreed as being allowable). Note: Agreement as to allowability is tentative and does not restrict further action by the examiner to the contrary.
- The signature of the examiner who conducted the interview (if Form is not an attachment to a signed Office action)

It is desirable that the examiner orally remind the applicant of his or her obligation to record the substance of the interview of each case unless both applicant and examiner agree that the examiner will record same. Where the examiner agrees to record the substance of the interview, or when it is adequately recorded on the Form or in an attachment to the Form, the examiner should check the appropriate box at the bottom of the Form which informs the applicant that the submission of a separate record of the substance of the interview as a supplement to the Form is not

It should be noted, however, that the Interview Summary Form will not normally be considered a complete and proper recordation of the interview unless it includes, or is supplemented by the applicant or the examiner to include, all of the applicable items required below concerning the substance of the interview.

A complete and proper recordation of the substance of any interview should include at least the following applicable items:

- 1) A brief description of the nature of any exhibit shown or any demonstration conducted,
- 2) an identification of the claims discussed,
- 3) an identification of the specific prior art discussed,
- 4) an identification of the principal proposed amendments of a substantive nature discussed, unless these are already described on the Interview Summary Form completed by the Examiner,
- 5) a brief identification of the general thrust of the principal arguments presented to the examiner,
  - (The identification of arguments need not be lengthy or elaborate. A verbatim or highly detailed description of the arguments is not required. The identification of the arguments is sufficient if the general nature or thrust of the principal arguments made to the examiner can be understood in the context of the application file. Of course, the applicant may desire to emphasize and fully describe those arguments which he or she feels were or might be persuasive to the examiner.)
- 6) a general indication of any other pertinent matters discussed, and
- 7) if appropriate, the general results or outcome of the interview unless already described in the Interview Summary Form completed by the examiner.

Examiners are expected to carefully review the applicant's record of the substance of an interview. If the record is not complete and accurate, the examiner will give the applicant an extendable one month time period to correct the record.

## **Examiner to Check for Accuracy**

If the claims are allowable for other reasons of record, the examiner should send a letter setting forth the examiner's version of the statement attributed to him or her. If the record is complete and accurate, the examiner should place the indication, "Interview Record OK" on the paper recording the substance of the interview along with the date and the examiner's initials.

Continuation of Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments:

In response to an indication by Mr. Dippert that the restriction requirement mailed 19 July 2000 did not include claims 32-42, Mr. Sisson indicated that claims 32-42, drawn to a kit, were to have been included in Group I. Accordingly, the groupings were to have been as follows:

- a) Group I, claims 1-10 and 32-42.
- b) Group II, claims 12-15.
- c) Group III, claims 16-31.

In response to inquiry by Mr. Dippert, Mr. Sisson indicated that a new computer readable form (CRF, e.g., floppy disk) of the Sequence Listing was needed along with a letter in stating that the CRF and the paper Sequence Listing are he same as required under 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d). Mr. Sisson also indicated that the Seuence Listing provided in the CRF needed to be presented as a single Sequene Listing and not as four separate files.

NOTICE TO COMPLY WITH RESTREMENTS FOR PATENT APPLI TIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 -1.825 for the following reason(s): This application clearly fails to comply with the requirements of 37 CFR 1.821-1.825. Applicant's attention is directed to these regulations, published at 114,00 29, May 15, 1990 and at 55 FR 18230, May 1, 1990. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c). 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing." The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d). The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e). 7. Other: -Applicant must provide: An initial or substitute computer readable form (CRF) copy of the "Sequence Listing" An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification A statement that the content of the paper and computer readable copies are the sar and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d) For questions regarding compliance with these requirements, please contac

For Rules Interpretation, call (703) 308-1123 For CRF submission help, call (703) 308-4212

For PatentIn software help, call (703) 557-0400

Please return a copy of this notice with your response.